1-3 of 3
Evan A Mulligan
Close
Sort by
Journal Articles

P B S-1086, a “Pan-Rel” Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells

Susan J Tudhope, BSc, PhD, Evan A Mulligan, BSc, PhD, Jill E Hunter, BSc, PhD, Geoffrey P Summerfield, MD, Scott Marshall, MD, Jonathan Wallis, MD, Helen Marr, Paul Evans, Chris Lowe, Barbara W Durkacz, BSc, PhD, Jie Zhang, PhD, Jeffrey Meshulam, BS, Kathryn Bobb, MS, Elaine Willmore, BSc, PhD
Journal: Blood
Blood (2012) 120 (21): 867.
https://doi.org/10.1182/blood.V120.21.867.867
Published: 2012
Journal Articles

Relationships Between Aberrant Activity of the NF-κB Subunits and Outcome In Chronic Lymphocytic Leukemia: The Dual Role of DNA Damage Sensor Enzymes

Evan A Mulligan, Jill E Hunter, Arabella EG Baird, Sarah Elliott, Geoffrey P Summerfield, Karen Hamlen, Chris Lowe, Jonathan Wallis, Stephany Veuger, Barbara W Durkacz, Elaine Willmore
Journal: Blood
Blood (2010) 116 (21): 3588.
https://doi.org/10.1182/blood.V116.21.3588.3588
Published: 2010
Journal Articles

ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA-Dependent Protein Kinase

Elaine Willmore, BSc, PhD, Ana Skowronska, Evan A Mulligan, PhD, G. Ahmed, Sarah Elliott, PhD, Geoffrey P Summerfield, Karen Hamlen, Chris Lowe, Barbara W Durkacz, Tanja Stankovic
Journal: Blood
Blood (2010) 116 (21): 433.
https://doi.org/10.1182/blood.V116.21.433.433
Published: 2010